GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
By Elana Gotkine HealthDay Reporter
THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease and related dementias (ADRDs) among people with type 2 diabetes (T2D), according to a study published online April 7 in JAMA Neurology.
Huilin Tang, Ph.D., from the University of Florida College of Pharmacy in Gainesville, and colleagues examined the risk for ADRDs associated with GLP-1 RAs and SGLT2is in people with T2D in a target trial emulation study using electronic health record data. There were 396,963 eligible patients with T2D, of whom 33,858 were included in the GLP-1 RA versus the other glucose-lowering drug (GLD) cohort; 34,185 in the SGLT2i versus the other GLD cohort; and 24,117 in the GLP-1 RA versus SGLT2i cohort.
The researchers found that in inverse probability of treatment weighting-weighted cohorts, the incidence rate of ADRD was lower in GLP-1 RA initiators versus other GLD initiators and in SGLT2i initiators versus other GLD initiators, yielding hazard ratios of 0.67 and 0.57, respectively. No significant difference was seen between GLP-1 RAs and SGLT2is.
"These results support the potential neuroprotections of GLP-1 RAs and SGLT2is and highlight their possible role in ADRD prevention strategies. The comparable association between GLP-1 RAs and SGLT2is provides flexibility in treatment choices while potentially offering cognitive benefits," the authors write.
Several authors disclosed ties to the pharmaceutical and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes
FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.